Throughout her career, Najla Guthrie has been hailed for both her revolutionary contributions to nutritional science and her accomplishments within the nutraceuticals industry. Her original research, which was conducted at the Centre for Human Nutrition at the University of Western Ontario, focused on the effects of citrus juices and their constituent flavonoids on breast cancer cells. Today, this study continues to generate media and scientific interest and has marked Najla as an expert within her field.
Najla has since published over 50 papers in peer-reviewed journals and has given numerous presentations at both the national and international levels. During this time, she has also acted as a founding shareholder for KGK Science, transitioning from a neutraceutical medicine researcher to President and CEO. Under her leadership, the company has successfully established and executed a novel strategic plan, one which leveraged its research infrastructure and financed the development of patented in-house products. She is responsible for the co-development of KGK’s Diabetinol and Dermytol, as well as the commercialization and licensing of Sytrinol. Additionally, Najla has brought KGK’s integrated research and product development team to a world-class level, with the group receiving international recognition for its efforts in nutraceutical science and cannabis research.
Currently, Najla is widely recognized as a global leader and sought-after spokesperson in the neutraceutical trade. She is also a lobbyist for the advancement of policy changes in the supplement and cannabis industries.